Azurity Pharmaceuticals recently announced the FDA approval of Nymalize (nimodipine) oral solution in a 30-mg/5-mL prefilled ENFit syringe. Nymalize is indicated for the improvement of neurological outcomes by decreasing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms irrespective of their postictus neurological condition (i.e., Hunt and Hess Grades I-V).

Richard Blackburn, CEO of Azurity Pharmaceuticals, stated, “Patients are our priority, and our purpose is to bring them new formulations and delivery systems that help them benefit from established medicines. Delivering Nymalize with ENFit syringes may offer patients and healthcare professionals a more secure, reliable drug administration through standardization.”

The Nymalize 30-mg/5-mL prefilled ENFit syringe may offer an additional layer of security for patients and healthcare professionals administering medication. The FDA recommends ENFit connectors, and extensive adoption of ENFit has commenced to replace traditional nasogastric tubing. An estimated 60% of all acute care facilities in the United States have implemented the use of ENFit.

Nymalize offers an effective alternative to capsule extraction for adult subarachnoid hemorrhage patients who cannot swallow capsules. It is available in ready-to-use, prefilled ENFit syringes (30 mg/5 mL), prefilled oral syringes (30 mg/5 mL and 60 mg/10 mL), and 8-ounce (237-mL) bottles. The use of Nymalize may help diminish the risk of fatal medication errors associated with nimodipine capsule extraction.

The Nymalize prefilled ENFit syringe will be available to order through a pharmaceutical wholesaler in the coming weeks. More information on this novel product can be found at www.nymalize.com.

The content contained in this article is for informational purposes only. The content is not intended to be a substitute for professional advice. Reliance on any information provided in this article is solely at your own risk.